Huntington DiseaseMAMOC-MHNCT07409597
Autobiographical Memory, Future Thought, and Eye Movements in Huntington's Disease
A study testing neuropsychological tests and Eye tracker use in people with Huntington Disease and Autobiographical Memory, run by University Hospital, Angers at 1 site in France.
Trial summary
Huntington's disease (HD) is a hereditary neurodegenerative disorder characterized by progressively worsening motor, cognitive, psychiatric, and behavioral deficits. Cognitive deficits occur early on, affecting in particular executive functions (inhibition, flexibility), decision-making, memory, attention (selective… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Huntington Disease, Autobiographical Memory
- What is being tested?
- neuropsychological tests and Eye tracker use
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 80 participants
- Where
- 1 siteFrance
- Study dates
- 1 Apr 2026to 1 Apr 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- For patients:
- Adults at inclusion
- Huntington's disease diagnosed and confirmed by genetic analysis
- Patients in the presymptomatic stage of HD with a motor UHDRS score ≤ 5 and patients in symptomatic stages 1-2 of HD with a motor UHDRS score > 5 and a CFT between 6 < CFT ≤ 13
- Patients who have given their written informed consent or consent from a third party
- Affiliated with or beneficiary of a social security system
Show all 14Show fewer
- For healthy controls:
- Pre-inclusion criteria
- Adults at inclusion
- Individuals with no history of neurological disorders (interview and clinical examination)
- Signature of informed consent to participate in the study
- Affiliated with or beneficiary of a social security system
- Matching in age (± 5 years), sex, and level of education with an HD patient included in the control group
- MMSE ≥ 24/30
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site
CHU Angers
Angers, 49933
Philippe ALLAIIN, Professor, +332 41 35 62 14, phallain@chu-angers.fr
About this study
Official title: Mémoire Autobiographique, pensée Future et Mouvements OCulaires Dans la Maladie de Huntington - MAMOC-MH
Huntington's disease (HD) is a hereditary neurodegenerative disorder characterized by progressively worsening motor, cognitive, psychiatric, and behavioral deficits. Cognitive deficits occur early on, affecting in particular executive functions (inhibition, flexibility), decision-making, memory, attention (selective, sustained), perceptual and visuospatial skills, and information processing speed.
More specifically, memory deficits quickly affect different memory systems (short-term memory, long-term memory, etc.), including autobiographical memory. Autobiographical memory is usually defined as a system that stores all the information (semantic component) and specific memories (episodic component) specific to an individual, accumulated from an early age. Autobiographical memory is now considered essential to the construction of a sense of identity and continuity. It is also considered indispensable for projecting into the future, otherwise known as "episodic future thinking," a fundamental human capacity that is both anticipatory and adaptive.
Read more
Autobiographical memory deficits remain largely unexplored in HD, with only three studies identified in the international literature on the subject, one of which is actually based on the same neuropsychological data as another, adding a neuroanatomical analysis focused on autobiographical memory. These studies show that the autobiographical recollections of patients with HD are mainly descriptive recollections of personal events lacking in detail, and that the abnormalities appear to be linked to the progressive degeneration of a vast cortico-subcortical brain network comprising the medial temporal cortex, the frontal cortex, and the posterior striatal and parietal regions. Deficits in episodic future thinking have never been explored in HD. A better understanding of the mechanisms underlying this type of cognitive impairment (recalling personal memories and mentally simulating future personal events) remains a major challenge today in improving the care of patients with HD.
Several recent studies have shown, in different pathological contexts (Alzheimer's disease, etc.), that the parallel use of neuropsychological tests (tasks and questionnaires) and an eye-tracking system allows for a much more accurate and in-depth examination of cognitive functions (for a review, see). In addition, eye movements, such as fixations and saccades, have been associated with the retrieval of autobiographical events . These movements better reflected the person's subjective experience, particularly with regard to the visual elements of mental imagery of recovered events. This suggests that the analysis of eye behavior could enrich the assessment of autobiographical memory, beyond the data provided by traditional tests.
The examination of eye movements is therefore, alongside neuropsychological testing, a promising non-invasive method for better understanding the characteristics of autobiographical memory in HD.
This project therefore aims to explore the autobiographical memory of HD patients by analyzing their eye activity during tasks involving the recall of personal events using standard neuropsychological tools. By identifying oculomotor markers associated with autobiographical memory disorders, this research could: (1) provide a better understanding of the neurocognitive profile of HD, (2) pave the way for more accurate diagnostic tools, and (3) form an important basis for the development of future interventions aimed at supporting memory function in this population.
- Conditions
- Huntington Disease, Autobiographical Memory
- Being tested
- neuropsychological tests, Eye tracker use
- Medical subject headings
- Huntington Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
neuropsychological testsOther
different neuropsycholocical tests
Eye tracker useOther
Eye movement assessment/recording is performed under two conditions: a "control" condition and an "autobiographical recall" condition.
| Study group | Role | What they receive |
|---|---|---|
| healthy patients | Active comparator | Not described Receives: Other: neuropsychological tests; Other: Eye tracker use |
| patients with Huntington's disease | Active comparator | Not described Receives: Other: neuropsychological tests; Other: Eye tracker use |
What is being measured
The primary outcome is the main question the study is designed to answer.
Assess the recall of personal memories and mental simulation of future personal events in patients with genetically confirmed HD, through analysis of the specificity
It will be assessed using the TEMPau specificity scale. This scale uses a Likert scale ranging from 0 to 4 points (0: no response or general information; 1: vague event without spatial-temporal context; 2: generic or specific event without spatial-temporal context; 3: specific event in a non-detailed spatial-temporal context; 4: specific event in a detailed spatial-temporal context). This scale allows two main scores to be collected for each period of life explored: 1) an overall autobiographical memory score counting all events, regardless of their nature (max.: 3 x 1 = 3) and 2) a strictly episodic score, counting only memories that meet all the criteria for episodicity, rated 4 (max.: 3 x 4 = 12). The scale also provides: 1) an overall autobiographical memory score for all four life periods explored (max.: 3 x 4 = 12) and an overall strictly episodic score, counting only memories that meet all the criteria for episodicity across all four periods, rated 4 (max.: 12 x 4 = 48).
Measured: inclusion
Assess the recall of personal memories and mental simulation of future personal events in patients with genetically confirmed HD through analysis of the phenomenology
self-questionnaire comprising eight items, measured on a Likert scale ranging from 1 to 4 points (1: no, that is completely untrue; 2: no, that is rather untrue; 3: yes, that is rather true; 4: yes, that is completely true). The 8 items are as follows: 1: I felt like I was reliving the original event; 2: I felt like I was travelling back in time to the moment when the event happened; 3: I don't just know that this event happened, I remember actually experiencing it; 4: I believe that the event in my memory actually happened as I remember it; 5: I can see and hear elements of the event in my mind; 6: I can now feel the emotions I felt when the event happened; 7: I can remember where the event took place; I can remember the time when the event occurred. This scale allows a phenomenological score to be obtained for each period of life explored (max.: 3 x 8 x 4 = 96) and an overall phenomenological score for all four periods of life explored (max.: 3 x 8 x 4 x 4 = 380).
Measured: inclusion
Assess the recall of personal memories and mental simulation of future personal events in patients with genetically confirmed HD through analysis of the self-defined nature
Each memory is evaluated according to six empirically based dimensions:
- the specificity of the event (rated from 0 to 4 according to TEMPau criteria, with 0 = extended or semantic memory, 4 = unique event, situated in time and space),
- identity relevance ('This memory reflects an important part of who I am')
- the presence of a lasting personal conflict or theme ('This memory is linked to an important theme or conflict in my life')
- emotional intensity ('This memory expresses a very strong or striking emotion')
- reflective integration ('This memory has helped me learn a personal lesson')
- frequency of mental access ('This is a memory I often think back on or talk about regularly')
The last five dimensions are assessed by self-questionnaire, on a Likert scale ranging from 1 to 4 (1 = not at all, 4 = completely). This combination gives an overall SDM score ranging from 5 (weakly self-defined memory) to 24.
Measured: inclusion
Assess the recall of personal memories and mental simulation of future personal events in patients with genetically confirmed HD through analysis of the emotional valence
It will be assessed using the 'Then' and 'Now' scale, which consists of asking the subject to evaluate (self-questionnaire), for each memory, on a Likert scale ranging from -3 to 3, how they felt at the time the event occurred and how they feel when they recall it.
Measured: inclusion
Assess the recall of personal memories and mental simulation of future personal events in patients with genetically confirmed HD through analysis of the degree of integration of memories
It will be assessed qualitatively using the definitions provided by Blagov and Singer (2004):
- Integrative memories: There is a shift away from narrative events and descriptions to make an additional statement about the importance or significance of the memory to the individual. A meaningful statement must go beyond simply saying that the memory is 'important', 'the most painful' or 'a memory I will never forget'. There must be an indication of why the memory is important and moving.
- Non-integrative memories: These are discussed in the manual and do not meet the requirements of integrative memories.
Measured: inclusion
Secondary outcomes (11)
To study the variation in pupil dilation characteristics during the recall of autobiographical memories.
Measured in millimeters (between 1.5 to 8 mm) with Pupil Labs Core monocular device
Measured: inclusion
To study the variation of eye movements during the recall of autobiographical memories (number).
number of fixation and saccades measured with Pupil Labs Core monocular device
Measured: inclusion
To study the variation of eye movements during the recall of autobiographical memories (duration).
duration of fixation and saccades measured with Pupil Labs Core monocular device
Measured: inclusion
Study the links between participants' temporal perspective (past, present, future)and their autobiographical performance
assessed using the ZTPI-short (Zimbardo Time Perspective Inventory - short version)
Measured: inclusion
analyse the current representation of the self (psychological, social, physical)
identity fluency task: through spontaneous verbal productions
Measured: inclusion
Evaluate the functional dimension of autobiographical memory (why we use it)
It will be assessed using the TALE-15 (Thinking About Life Experiences) questionnaire
Measured: inclusion
Investigate clinical and cognitive data from routine assessments with UHDRS
using Unified Huntington's Disease Rating Scale; This scale is divided into several subscales grouping together different tests assessing: motor difficulties (dysarthria, dystonia, choreic movements, bradykinesia, gait disorders, etc.), cognitive difficulties [flexibility (literal verbal fluency), processing speed (Symbol Digit Modalities Test), inhibition (Stroop task)], level of independence, and functional difficulties. The TFC (Total Functional Capacity) is a specific subscale of the UHDRS that assesses patients' functional independence. It takes into account five areas: occupational capacity, financial management, domestic management, independence in activities of daily living, and degree of care required. The overall score ranges from 0 (complete dependence) to 13 (complete independence). A high score indicates preserved independence, while a low score reflects a significant loss of independence. TFC is a benchmark indicator of disease severity and progression.
Measured: inclusion
Investigate clinical and cognitive data from routine assessments with MMSE
overall efficiency measured using Mini Mental Scale examination
Measured: inclusion
Investigate clinical and cognitive data from routine assessments with categorical fluency
flexibility measured using categorical fluency
Measured: inclusion
Investigate clinical and cognitive data from routine assessments with Trail making Test
flexibility measured using Trail making Test
Measured: inclusion
Investigate clinical and cognitive data from routine assessments with PBA-s
Behaviour troubles measured with Problem Behaviours Assesment scale
Measured: inclusion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Feb 2026
- Study start1 Apr 2026 (estimated)
- Primary completion1 Apr 2029 (estimated)
- Study completion1 Apr 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Huntington DiseaseStudies of the same condition, open and under way.
- More trials run by University Hospital, AngersThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Angers
- Sponsor type
- Other government
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07409597
- Sponsor's protocol ID
- 49RC25_0372
- Other IDs
- ANSM
- Acronym
- MAMOC-MH
- Status last verified
- Feb 2026
- First submitted
- 3 Feb 2026
- Last updated
- 6 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Data will be shared upon reasonable request. Only de-identified data will be shared. Any data collected during the study may be shared. The protocol will be shared initially. Other documents may be shared at a later date upon request (e.g., the CRF to allow a collaborator to select the data they wish to access). The recipients of the data will be researchers. The data will be available for any purpose deemed relevant by the study investigator, based on a protocol provided by the requester, after verification of the obtaining of regulatory approvals, including the favorable opinion of an ethics committee.
Study at a glance
From the registry record, last updated by the sponsor on 6 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Mémoire Autobiographique, pensée Future et Mouvements OCulaires Dans la Maladie de Huntington - MAMOC-MH
- ClinicalTrials.gov ID
- NCT07409597
- Acronym / sponsor ID
- MAMOC-MH / 49RC25_0372
- Conditions
- Huntington Disease, Autobiographical Memory
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- University Hospital, AngersOther government
- Study start
- 1 Apr 2026 (estimated)
- Primary completion
- 1 Apr 2029 (estimated)
- Study completion
- 1 Apr 2029 (estimated)
- First posted
- 13 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Huntington's disease (HD) is a hereditary neurodegenerative disorder characterized by progressively worsening motor, cognitive, psychiatric, and behavioral deficits. Cognitive deficits occur early on, affecting in particular executive functions (inhibition, flexibility), decision-making, memory, attention (selective, sustained), perceptual and visuospatial skills, and information processing speed.
More specifically, memory deficits quickly affect different memory systems (short-term memory, long-term memory, etc.), including autobiographical memory. Autobiographical memory is usually defined as a system that stores all the information (semantic component) and specific memories (episodic component) specific to an individual, accumulated from an early age. Autobiographical memory is now considered essential to the construction of a sense of identity and continuity. It is also considered indispensable for projecting into the future, otherwise known as "episodic future thinking," a fundamental human capacity that is both anticipatory and adaptive.
Autobiographical memory deficits remain largely unexplored in HD, with only three studies identified in the international literature on the subject, one of which is actually based on the same neuropsychological data as another, adding a neuroanatomical analysis focused on autobiographical memory. These studies show that the autobiographical recollections of patients with HD are mainly descriptive recollections of personal events lacking in detail, and that the abnormalities appear to be linked to the progressive degeneration of a vast cortico-subcortical brain network comprising the medial temporal cortex, the frontal cortex, and the posterior striatal and parietal regions. Deficits in episodic future thinking have never been explored in HD. A better understanding of the mechanisms underlying this type of cognitive impairment (recalling personal memories and mentally simulating future personal events) remains a major challenge today in improving the care of patients with HD.
Several recent studies have shown, in different pathological contexts (Alzheimer's disease, etc.), that the parallel use of neuropsychological tests (tasks and questionnaires) and an eye-tracking system allows for a much more accurate and in-depth examination of cognitive functions (for a review, see). In addition, eye movements, such as fixations and saccades, have been associated with the retrieval of autobiographical events . These movements better reflected the person's subjective experience, particularly with regard to the visual elements of mental imagery of recovered events. This suggests that the analysis of eye behavior could enrich the assessment of autobiographical memory, beyond the data provided by traditional tests.
The examination of eye movements is therefore, alongside neuropsychological testing, a promising non-invasive method for better understanding the characteristics of autobiographical memory in HD.
This project therefore aims to explore the autobiographical memory of HD patients by analyzing their eye activity during tasks involving the recall of personal events using standard neuropsychological tools. By identifying oculomotor markers associated with autobiographical memory disorders, this research could: (1) provide a better understanding of the neurocognitive profile of HD, (2) pave the way for more accurate diagnostic tools, and (3) form an important basis for the development of future interventions aimed at supporting memory function in this population.
Study design
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| healthy patients | Active comparator | Other: neuropsychological tests, Other: Eye tracker use |
| patients with Huntington's disease | Active comparator | Other: neuropsychological tests, Other: Eye tracker use |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (14 listed)
- Adults at inclusion
- Huntington's disease diagnosed and confirmed by genetic analysis
- Patients in the presymptomatic stage of HD with a motor UHDRS score ≤ 5 and patients in symptomatic stages 1-2 of HD with a motor UHDRS score > 5 and a CFT between 6 < CFT ≤ 13
- Patients who have given their written informed consent or consent from a third party
- Affiliated with or beneficiary of a social security system
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| neuropsychological testsdifferent neuropsycholocical tests | Other | healthy patients, patients with Huntington's disease |
| Eye tracker useEye movement assessment/recording is performed under two conditions: a "control" condition and an "autobiographical recall" condition. | Other | healthy patients, patients with Huntington's disease |
Primary outcome
Assess the recall of personal memories and mental simulation of future personal events in patients with genetically confirmed HD, through analysis of the specificity
Time frame: inclusion
It will be assessed using the TEMPau specificity scale. This scale uses a Likert scale ranging from 0 to 4 points (0: no response or general information; 1: vague event without spatial-temporal context; 2: generic or specific event without spatial-temporal context; 3: specific event in a non-detailed spatial-temporal context; 4: specific event in a detailed spatial-temporal context). This scale allows two main scores to be collected for each period of life explored: 1) an overall autobiographical memory score counting all events, regardless of their nature (max.: 3 x 1 = 3) and 2) a strictly episodic score, counting only memories that meet all the criteria for episodicity, rated 4 (max.: 3 x 4 = 12). The scale also provides: 1) an overall autobiographical memory score for all four life periods explored (max.: 3 x 4 = 12) and an overall strictly episodic score, counting only memories that meet all the criteria for episodicity across all four periods, rated 4 (max.: 12 x 4 = 48).
Assess the recall of personal memories and mental simulation of future personal events in patients with genetically confirmed HD through analysis of the phenomenology
Time frame: inclusion
self-questionnaire comprising eight items, measured on a Likert scale ranging from 1 to 4 points (1: no, that is completely untrue; 2: no, that is rather untrue; 3: yes, that is rather true; 4: yes, that is completely true). The 8 items are as follows: 1: I felt like I was reliving the original event; 2: I felt like I was travelling back in time to the moment when the event happened; 3: I don't just know that this event happened, I remember actually experiencing it; 4: I believe that the event in my memory actually happened as I remember it; 5: I can see and hear elements of the event in my mind; 6: I can now feel the emotions I felt when the event happened; 7: I can remember where the event took place; I can remember the time when the event occurred. This scale allows a phenomenological score to be obtained for each period of life explored (max.: 3 x 8 x 4 = 96) and an overall phenomenological score for all four periods of life explored (max.: 3 x 8 x 4 x 4 = 380).
Assess the recall of personal memories and mental simulation of future personal events in patients with genetically confirmed HD through analysis of the self-defined nature
Time frame: inclusion
Each memory is evaluated according to six empirically based dimensions: 1. the specificity of the event (rated from 0 to 4 according to TEMPau criteria, with 0 = extended or semantic memory, 4 = unique event, situated in time and space), 2. identity relevance ('This memory reflects an important part of who I am') 3. the presence of a lasting personal conflict or theme ('This memory is linked to an important theme or conflict in my life') 4. emotional intensity ('This memory expresses a very strong or striking emotion') 5. reflective integration ('This memory has helped me learn a personal lesson') 6. frequency of mental access ('This is a memory I often think back on or talk about regularly') The last five dimensions are assessed by self-questionnaire, on a Likert scale ranging from 1 to 4 (1 = not at all, 4 = completely). This combination gives an overall SDM score ranging from 5 (weakly self-defined memory) to 24.
Assess the recall of personal memories and mental simulation of future personal events in patients with genetically confirmed HD through analysis of the emotional valence
Time frame: inclusion
It will be assessed using the 'Then' and 'Now' scale, which consists of asking the subject to evaluate (self-questionnaire), for each memory, on a Likert scale ranging from -3 to 3, how they felt at the time the event occurred and how they feel when they recall it.
Assess the recall of personal memories and mental simulation of future personal events in patients with genetically confirmed HD through analysis of the degree of integration of memories
Time frame: inclusion
It will be assessed qualitatively using the definitions provided by Blagov and Singer (2004): * Integrative memories: There is a shift away from narrative events and descriptions to make an additional statement about the importance or significance of the memory to the individual. A meaningful statement must go beyond simply saying that the memory is 'important', 'the most painful' or 'a memory I will never forget'. There must be an indication of why the memory is important and moving. * Non-integrative memories: These are discussed in the manual and do not meet the requirements of integrative memories.
11 secondary outcomes
To study the variation in pupil dilation characteristics during the recall of autobiographical memories.
Time frame: inclusion
To study the variation of eye movements during the recall of autobiographical memories (number).
Time frame: inclusion
To study the variation of eye movements during the recall of autobiographical memories (duration).
Time frame: inclusion
Study the links between participants' temporal perspective (past, present, future)and their autobiographical performance
Time frame: inclusion
analyse the current representation of the self (psychological, social, physical)
Time frame: inclusion
Evaluate the functional dimension of autobiographical memory (why we use it)
Time frame: inclusion
Investigate clinical and cognitive data from routine assessments with UHDRS
Time frame: inclusion
Investigate clinical and cognitive data from routine assessments with MMSE
Time frame: inclusion
Investigate clinical and cognitive data from routine assessments with categorical fluency
Time frame: inclusion
Investigate clinical and cognitive data from routine assessments with Trail making Test
Time frame: inclusion
Investigate clinical and cognitive data from routine assessments with PBA-s
Time frame: inclusion
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Apr 2026.
- Individual participant dataSharing planned: Yes. Data will be shared upon reasonable request. Only de-identified data will be shared. Any data collected during the study may be shared. The protocol will be shared initially. Other documents may be shared at a later date upon request (e.g., the CRF to allow a collaborator to select the data they wish to access). The recipients of the data will be researchers. The data will be available for any purpose deemed relevant by the study investigator, based on a protocol provided by the requester, after verification of the obtaining of regulatory approvals, including the favorable opinion of an ethics committee.
Related trials for Huntington Disease
RecruitingPhase 2/3
Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease
Huntington Disease
RecruitingPhase 3
Pridopidine Phase 3 Study in Huntington's Disease
Huntington Disease
Not yet recruiting
Creatine and Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation Plus Home-Based Exercise for Sarcopenia in Huntington's Disease
Huntington Disease, Sarcopenia
Recruiting
Feasibility and Acceptability of an LLM-based Chatbot for Family Caregivers: Evaluation Study
Caregivers
RecruitingObservational study
Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders
Invasive PreNatal Diagnosis in a Context of Family History of Single-gene Disorders, Including, Sickle Cell Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing neuropsychological tests and Eye tracker use in people with Huntington Disease and Autobiographical Memory, run by University Hospital, Angers at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 6 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Philippe ALLAIN, Professor (+332 41 35 62 14, phallain@chu-angers.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Assess the recall of personal memories and mental simulation of future personal events in patients with genetically confirmed HD, through analysis of the specificity (time frame: inclusion). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Apr 2026.